Loading...

Home
ETF
SYRE

SYRE

-

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

Overview Technical News

Most Trusted AI Platform for Winning Trades

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

Home
Contact
About Us
Press
Privacy
Terms of Service
Service Terms of Use

Resources

Blog
Tutorial
Help Center
Affiliate Program

Markets

Market Analysis
Crypto
Featured Screeners
AI Earnings Calendar
Market Movers
Stock Monitor
Economic Calendar
All US Stocks
All Cryptos

Tools

Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator

Features

QuantAI Alpha Pick
SwingMax Portfolio
Swing Trading
AI Stock Picker
Whales Auto Tracker
Daytrading Center
Patterns Detection
AI Screener
Financial AI Agent
Backtesting Playground
AI Earnings Prediction
Stock Monitor
Technical Analysis

News

Overview
Top News
Daily Market Brief
Earnings Analysis
Newswire
Stock News
Crypto News
Institution News
Congress News
Monitor News

Compare

TradingView
SeekingAlpha

SYRE News

VR Adviser, LLC Increases Stake in Spyre Therapeutics by 1 Million Shares

Mar 19 2026NASDAQ.COM

VR Adviser Increases Stake in Spyre Therapeutics by 1 Million Shares

Mar 19 2026Fool

VR Adviser, LLC Reduces Stake in Ocular Therapeutix

Mar 18 2026Fool

VR Adviser, LLC Sells Shares of Ocular Therapeutix

Mar 18 2026NASDAQ.COM

VR Adviser Increases Stake in Savara by Over 1 Million Shares

Mar 15 2026NASDAQ.COM

VR Adviser Increases Stake in Savara by Over 1 Million Shares

Mar 15 2026Fool

Commodore Capital Increases Stake in Spyre Therapeutics

Feb 23 2026Fool

Spyre Therapeutics Grants Stock Options to Employees

Feb 06 2026Newsfilter

Spyre Therapeutics CEO Sells 15,000 Shares for $460K

Jan 11 2026Fool

Spyre Therapeutics CEO Cameron Turtle Sells 15,000 Shares for Over $460,000

Jan 11 2026NASDAQ.COM

Spyre Grants 42,000 Stock Options to Six Employees as Inducement Awards

Jan 08 2026Globenewswire

Biotech Sector Sustains After-Hours Trading Gains

Dec 18 2025NASDAQ.COM

Spyre Therapeutics Grants 20,300 Stock Options to Employees as Inducement Awards

Dec 05 2025Globenewswire

Spyre Grants 20,300 Stock Options to Employees Under Equity Inducement Plan

Dec 05 2025Newsfilter

Chevron Analyst Becomes Optimistic; Check Out the Top 5 Upgrades for Monday

Dec 01 2025Benzinga

Top Analysts Recommend 3 Best Stocks to Purchase as of December 1, 2025

Dec 01 2025TipRanks